MediWound Stock (NASDAQ:MDWD)
Previous Close
$17.20
52W Range
$10.06 - $24.00
50D Avg
$17.28
200D Avg
$17.21
Market Cap
$177.87M
Avg Vol (3M)
$45.82K
Beta
0.84
Div Yield
-
MDWD Company Profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MDWD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SANA | Sana Biotechnology, Inc. |
| MRUS | Merus N.V. |
| AVTE | Aerovate Therapeutics, Inc. |
| RNA | Avidity Biosciences, Inc. |
| STRO | Sutro Biopharma, Inc. |
| GBIO | Generation Bio Co. |
| REPL | Replimune Group, Inc. |
| OCUL | Ocular Therapeutix, Inc. |
| KRON | Kronos Bio, Inc. |
| DYAI | Dyadic International, Inc. |
| VCYT | Veracyte, Inc. |
| KROS | Keros Therapeutics, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| INBX | Inhibrx Biosciences, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| SWTX | SpringWorks Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| NKTX | Nkarta, Inc. |